{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:47:01Z","timestamp":1786978021767,"version":"build-2736575974"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Huntington disease (HD) is a hereditary neurodegenerative disorder with a hallmark feature of chorea. While no disease\u2010modifying therapies currently exist for HD, symptomatic treatment of HD\u2010associated chorea includes US Food and Drug Administration\u2013approved vesicular monoamine transporter type 2 inhibitors\u2014tetrabenazine and deutetrabenazine. Deutetrabenazine was more recently approved (2017), and while structurally similar to tetrabenazine, deutetrabenazine has a unique pharmacokinetic profile that allows for a longer half\u2010life, reduced plasma fluctuations, and less frequent dosing. In pivotal trials, deutetrabenazine seemed to have an improved safety and tolerability profile over tetrabenazine but real\u2010world data to confirm this are lacking. Here, we evaluate our real\u2010world clinical experience with deutetrabenazine for HD\u2010associated chorea. We performed a retrospective chart review of all patients with HD who initiated treatment with deutetrabenazine from January 2017 to May 2019 at the University of Alabama at Birmingham. Total maximal chorea scores, patient\u2010reported subjective efficacy, dosing information, and subjective reports of adverse events (AEs) were abstracted for each patient. Our review included 58 patients with a mean length of treatment of 476.4 days. In the reviewed time period, the mean treatment difference in total maximal chorea scores was 4.4. The combined total rate of occurrence of any AEs was relatively low, at 32.8%, and the most commonly reported AEs were sedation (15.5%), insomnia (6.9%), and diarrhea (3.4%). Our real\u2010world data support current literature indicating that deutetrabenazine is an effective and well\u2010tolerated treatment for HD\u2010associated chorea. Further studies repeating this on a larger scale, across a greater geography and practice pattern, are needed.<\/jats:p>","DOI":"10.1002\/jcph.2336","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T05:17:37Z","timestamp":1691731057000},"page":"178-181","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real\u2010World Experience With Deutetrabenazine for Huntington Disease Chorea"],"prefix":"10.1002","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2450-636X","authenticated-orcid":false,"given":"Kendall","family":"Curtis","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Medicine  Pittsburgh PA USA"},{"name":"Department of Neurology Division of Movement Disorders University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Sung","sequence":"additional","affiliation":[{"name":"Department of Neurology Division of Movement Disorders University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.15.1.109"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449184"},{"key":"e_1_2_10_7_1","first-page":"690","article-title":"Tetrabenazine (Xenazine), an FDA\u2010approved treatment option for Huntington's disease\u2010related chorea","volume":"33","author":"Yero T","year":"2008","journal-title":"P T"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2014.943184"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21222"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12483"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40734-017-0051-5"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S138828"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1352"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T03:55:23Z","timestamp":1706500523000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1002\/jcph.2336"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2336","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"assertion":[{"value":"2023-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}